ESMO 2023 INDUSTRY SATELLITE SYMPOSIUM

## **Putting the patient first:** Considering treatment choice and maximising quality of life in mHSPC



Dear {{accTitle}} {{accLname}},

If you are attending ESMO, we would like to invite you to attend the Astellassponsored symposium, Putting the patient first: Considering treatment choice and maximising quality of life in mHSPC, on Sunday 22 October, 13:00–14:00 CEST, at the ESMO Congress 2023 in Madrid, Spain.

During this insightful symposium, the faculty will discuss major advances in the outcomes of patients with mHSPC and focus on how to put the patient first to maximise quality of life. Since patients receiving new therapies survive for many years, there will be conversations about improving quality of life and strategies to enhance survival outcomes for more patients with mHSPC.

## **Faculty**



Professor Christopher Sweeney (Chair) Director of SAIGENCI and Professor of Medicine, University of Adelaide, Adelaide, Australia




Professor Heather Payne
Consultant Clinical Oncologist,
University College London
Hospitals NHS Foundation Trust,
and Clinical Director,
The Prostate Centre, London, UK



Doctor Javier Puente
Associate Professor,
Faculty of Medicine, Universidad
Complutense de Madrid, and
GU Cancer Unit, Medical
Oncology Department,
Hospital Clínico San Carlos,
Madrid, Spain

For further details on this unique symposium and why you should attend, here is a short video from the Chair, Professor Christopher Sweeney:



Session	Speaker(s)
Welcome and introduction	Professor Sweeney
Reinforcing standard of care: The benefits of early treatment intensification in patients with mHSPC	<ul> <li>Professor Payne and</li> <li>Doctor Puente, facilitated by Professor Sweeney</li> </ul>
The importance of first-line treatment choice in patients with mHSPC	
Maximising quality of life: Holistic approaches in the management of patients with mHSPC	
Q&A	
Closing remarks	Professor Sweeney

We hope that you can attend.

## Warm regards,

{{userName}}

{{User.Title}}

{{userPhoto}}

Astellas Pharma Australia Pty Ltd Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113

Mobile: {{User.MobilePhone}} Email: {{userEmailAddress}}

ESMO, European Society for Medical Oncology; mHSPC, metastatic hormone-sensitive prostate cancer; SAiGENCI, South Australian Immunogenomics Cancer Institute.

This symposium is fully funded and organised by Astellas. It is intended for an international audience of healthcare professionals only.

©2023 Astellas Pharma Inc. Astellas and the flying star logo are registered trademarks of Astellas Pharma Inc.

This email contains information about Astellas' products, services or events. For more information on how we use and protect your information, please read our <u>Privacy Policy</u>. You have received this email because you have previously given consent to receive information regarding Astellas' products, services or events. You can withdraw your consent by clicking <u>unsubscribe</u>, or by emailing our privacy officer at <u>privacyofficer-au@astellas.com</u>.

XTANDI<sup>™</sup> is a registered trademark of Astellas Pharma Inc. Astellas Pharma Australia Pty Ltd. ABN 81 147 915 482. Suite 2.01, 2 Banfield Road, Macquarie Park, NSW 2113.



